a virtually safe blood supply cure for anemia reduced spread of hepatitis saving lives after heart attacks slowing the progression multiple sclerosis better quality life diabetics longer cancer patients reducing debilitating effects rheumatoid arthritis hiv infection improved outcomes chronic c market capitalization biotechnology industry at end 1999 was 312 billion estimated sales all biotech products 18 by 13 4 9 spent on research in 1998 top five companies 121 400 per employee r&d compared with 30 600 pharma us continues to dominate 1 283 373 publicly traded total employees greater than 150 000 recombinant dna insulin hgh epo and interferon il 2 t pa pdgf vaccines etc monoclonal antibodies reopro rituxan herceptin small molecule compounds viracept agenerase gene therapy combinatorial chemistry now deployed broadly affymax alanex capabilities chiron vertex biogen pharmacopeia axys relying more heavily partnerships investing internal protein therapeutics development become science
